Correlation of Apobec mRNA Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Mullane, Stephanie A ^a   Werner, Lillian ^a,b   Rosenberg, Jonathan ^c   Signoretti, Sabina ^a,d   Callea, Marcella ^a   Choueiri, Toni K ^a,b,d   Freeman, Gordon J ^b,d   Bellmunt, Joaquim ^a,b,d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3 PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; CYTOSINE DEAMINASE; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1;

BLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR CELL LINE; UROTHELIUM;

B7-H1 ANTIGEN; CELL LINE, TUMOR; CYTOSINE DEAMINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA, MESSENGER; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84974602731     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27702     Document Type: Article

References (54)

1. R. L. Siegel, K. D. Miller & A. Jemal. Cancer statistics, 2015. CA Cancer J Clin 65, 5-29 (2015).
2. D. S. Kaufman, W. U. Shipley & A. S. Feldman. Bladder cancer. Lancet 374, 239-249 (2009).
3. P. Liu, C. M. Carvalho, P. J. Hastings & J. R. Lupski. Mechanisms for recurrent and complex human genomic rearrangements. Curr Opin Genet Dev 22, 211-220 (2012).
4. R. Suspène et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci USA 108, 4858-4863 (2011).
5. R. C. Beale et al. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol 337, 585-596 (2004).
6. E. W. Refsland et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV- 1 restriction. Nucleic Acids Res 38, 4274-4284 (2010).
7. C. G. A. R. Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
8. L. B. Alexandrov et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
9. M. S. Lawrence et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
10. S. A. Roberts et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45, 970-976 (2013).
11. J. P. O'Shea et al. pLogo: a probabilistic approach to visualizing sequence motifs. Nat Methods 10, 1211-1212 (2013).
12. S. Nik-Zainal et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet 46, 487-491 (2014).
13. S. A. Roberts et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell 46, 424-435 (2012).
14. S. Nik-Zainal et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
15. M. B. Burns et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366-370 (2013).
16. M. Shinohara et al. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep 2, 806 (2012).
17. B. J. Taylor et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2, e00534 (2013).
18. E. M. Van Allen et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4, 1140-1153 (2014).
19. M. L. Ascierto et al. An immunologic portrait of cancer. J Transl Med 9, 146 (2011).
20. R. Wang et al. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res 69, 3810-3818 (2009).
21. M. Riester et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18, 1323-1333 (2012).
22. M. Sanchez-Carbayo, N. D. Socci, J. Lozano, F. Saint & C. Cordon-Cardo. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24, 778-789 (2006).
23. T. K. Choueiri et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25, 2178-2184 (2014).
24. J. Bellmunt et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol (2015).
25. M. Callea et al. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res 3, 1158-1164 (2015).
26. J. Bellmunt et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18, 3247-3255 (2000).
27. N. A. Rizvi et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
28. E. Plimack. (Journal of Clinical Oncology, ASCO, 2015), vol. 33.
29. D. Petrylak. (Journal of Clinical Oncology, ASCO, 2015), chap. (suppl 7; abstr 297).
30. E. R. Plimack, S. Gupta, J. Bellmunt, R. Berger, B. Montgomery, E. J. Gonzalez, J. Pulini et al. (Annals of Oncology 25, 2014), vol. no. suppl 4.
31. J. Hoffman-Censits, P. Grivas. Ed. (J Clin Oncol 34, 2016 (suppl 2S; abstr 355), IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)).
32. S. Negrini, V. G. Gorgoulis & T. D. Halazonetis. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11, 220-228 (2010).
33. O. M. Sieber, K. Heinimann & I. P. Tomlinson. Genomic instability-the engine of tumorigenesis? Nat Rev Cancer 3, 701-708 (2003).
34. K. Chan et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet (2015).
35. S. A. Roberts & D. A. Gordenin. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 14, 786-800 (2014).
36. J. F. Hultquist et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85, 11220-11234 (2011).
37. T. C. G. A. Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
38. C. Chaipan, J. L. Smith, W. S. Hu & V. K. Pathak. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol 87, 444-453 (2013).
39. E. Miyagi et al. Stably expressed APOBEC3F has negligible antiviral activity. J Virol 84, 11067-11075 (2010).
40. M. A. Langlois, R. C. Beale, S. G. Conticello & M. S. Neuberger. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res 33, 1913-1923 (2005).
41. T. Powles et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
42. J. Rosenberg. (Annals of Oncology, 2015).
43. A. T. Parsa et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13, 84-88 (2007).
44. G. Xue et al. Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. J Natl Cancer Inst 107, (2015).
45. A. Snyder, J. D. Wolchok & T. A. Chan. Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med 372, 783 (2015).
46. E. M. Van Allen et al. Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation. Cancer Immunol Res (2015).
47. D. T. Le et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372, 2509-2520 (2015).
48. C. G. A. R. Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209 (2014).
49. L. Zhang et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 96, 597-611 (2015).
50. J. Bellmunt et al. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS One 10, e0124711 (2015).
51. E. M. Van Allen et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science (2015).
52. B. A. Walker et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun 6, 6997 (2015).
53. H. Beltran et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol 1, 466-474 (2015).
54. A. D'Incecco et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112, 95-102 (2015).